BioSpace News Archive

Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, will participate in the following upcoming investor conferences.

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced results from a preclinical study of RKER-012 on pulmonary arterial pressure and right ventricle hypertrophy in an established rodent model of pulmonary arterial hypertension (“PAH”) at the American Thoracic Society (“ATS”) International Conference held May 13 through 18, 2022.

XOMA Corporation announced its Chairman and Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, at 10:00 AM ET.

Talaris Therapeutics, Inc. announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.

Celyad Oncology SA announced that the Company plans to participate virtually at the upcoming H.C. Wainwright Global Investment Conference, May 23 – 26, 2022.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), will be presenting data describing the immunological profile of CBP-201 based on preclinical experiments, demonstrating reductions in clinically validated biomarkers of Th2-driven inflammation.

Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present virtually at the 2022 H.C. Wainwright Global Life Sciences Conference taking place May 23-26, 2022.

MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the Company’s management will participate in the following investor conference in May 2022.